<DOC>
	<DOCNO>NCT00000629</DOCNO>
	<brief_summary>Primary objective : To study pharmacokinetic interaction zidovudine ( AZT ) valproic acid asymptomatic HIV-infected patient , characterize AZT 's oral bioavailability , plasma elimination half-time , plasma level , urinary excretion AZT , 5'-O-glucuronide ( GAZT ) , 3'-amino-3'-deoxythymidine ( AMT ) . Secondary objective : To establish safety short-term administration AZT valproic acid combination regard hematologic parameter liver function asymptomatic HIV-infected patient . Preliminary study use human liver tissue show valproic acid inhibits metabolic inactivation zidovudine ( AZT ) , may prolong plasma half-life AZT thus prolong duration drug 's effect body .</brief_summary>
	<brief_title>The Effects Valproic Acid Zidovudine Glucuronidation Pharmacokinetics HIV-Infected Patients .</brief_title>
	<detailed_description>Preliminary study use human liver tissue show valproic acid inhibits metabolic inactivation zidovudine ( AZT ) , may prolong plasma half-life AZT thus prolong duration drug 's effect body . Six asymptomatic HIV-infected patient treat AZT orally every 8 hour day 1 4 , single dose day 5 ( 8 hour fast ) , follow pharmacokinetic sampling . On day 6 9 , patient receive AZT orally every 8 hour combination valproic acid ( low dose first 5 patient higher dose patient 6 7 ) orally every 8 hour . On day 10 , AZT 1 2 dos valproic acid give orally single dos , follow pharmacokinetic sampling . AZT continue alone orally every 8 hour day 11 14 , resume patient 's usual dose begin day 15 . Per 03/09/92 amendment , dose schedule may modify slightly accommodate patient schedule conflict .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Vitamins already take prior start therapy . Patients must : Asymptomatic HIV infection . CD4 count 300 650 . Prior Medication : Required : AZT dos 500 1200 mg/day least 6 week prior enrollment . Allowed : Aspirin , Tylenol , ibuprofen 48 hour prior start therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Positive Hepatitis B surface antigen clinical evidence chronic active hepatitis type . Signs symptom HIV infection include oral candidiasis , history multidermatomal zoster , unexplained weight loss excess 10 percent body weight past 6 month , chronic diarrhea , history AIDSdefining opportunistic infection . Concurrent Medication : Excluded : Concomitant medication ( AZT ) 14 day prior start therapy . Patients follow prior condition exclude : History AZT intolerance include hematologic , hepatic , and/or neurologic toxicity . History seizure . History antiepileptic within past 10 year . History abnormal bleeding intrinsic extrinsic coagulopathy . Signs symptom HIV infection include oral candidiasis , history multidermatomal zoster , unexplained weight loss excess 10 percent body weight past 6 month , chronic diarrhea , history AIDSdefining opportunistic infection . Prior Medication : Excluded : Antiepileptics within past 10 year . Prior valproic acid . Concomitant medication ( AZT ) within 14 day enrollment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>Valproic Acid</keyword>
	<keyword>Zidovudine</keyword>
</DOC>